Pharming Group N.V. (LON:0QCO)

Market Cap	437.82M
Revenue (ttm)	237.39M
Net Income (ttm)	-9.46M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,588
Average Volume	68,314
Open	0.7030
Previous Close	0.7090
Day's Range	0.6985 - 0.7080
52-Week Range	0.5375 - 1.0081
Beta	0.60
RSI	50.18
Earnings Date	May 8, 2025

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also dev...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1988
• Employees: 404
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QCO

Financial Performance

In 2024, Pharming Group's revenue was $297.20 million, an increase of 21.15% compared to the previous year's $245.32 million. Losses were -$11.84 million, 12.3% more than in 2023.

Financial numbers in USD